Dermik

Dermik Laboratories was a prominent pharmaceutical company dedicated to the development and commercialization of dermatological therapies. The company established a strong market presence with a portfolio addressing conditions such as acne, rosacea, and actinic keratosis, as well as aesthetic treatments. Key products included BenzaClin, a leading topical acne treatment, and Sculptra, an injectable filler for facial fat loss. Originally a subsidiary of Sanofi-Aventis, Dermik was acquired by Valeant Pharmaceuticals in 2011 for approximately $425 million. This acquisition allowed Valeant to significantly expand its presence in the dermatology and aesthetics sectors. Today, the Dermik brand and its legacy products are managed under the Bausch Health Companies umbrella.